10-Q: Akebia Therapeutics Reports Profitable Q1 2025 Driven by Vafseo Launch and Auryxia Sales

Akebia Therapeutics achieves profitability in Q1 2025, driven by the launch of Vafseo and increased Auryxia sales, while navigating Auryxia's loss of exclusivity.

Summary

• Akebia Therapeutics reports a net income of $6.1 million for the quarter ended March 31, 2025, a significant turnaround from the $17.9 million net loss in the same period of 2024.
• Total revenue increased by 76% to $57.3 million, driven by the launch of Vafseo and increased sales of Auryxia.
• Vafseo contributed $12.0 million in product revenue following its market entry in January 2025.
• Auryxia sales reached $43.8 million, including sales of the authorized generic version.
• The company's cash and cash equivalents stood at $113.4 million as of March 31, 2025.
• Akebia believes its current cash resources and expected revenue will be sufficient to fund its operating plan for at least the next twelve months.
• The company is managing Auryxia's loss of exclusivity in March 2025, with an authorized generic version now available.
• Akebia is exploring label expansion opportunities for Vafseo and advancing its pipeline of HIF-based molecules.
• The company is obligated to pay CSL Vifor decreasing quarterly tiered royalty payments ranging from a high single-digit percentage of the Company's net sales of Vafseo up to $450.0 million to mid-single digit percentage of the Company's net sales of Vafseo above $450.0 million, in each case, in the U.S. during a calendar year.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. While the company achieved profitability and launched a new product, it also faces challenges related to generic competition and regulatory compliance. The overall outlook is cautiously optimistic.

Positives

• The company achieved profitability in Q1 2025.
• Vafseo's launch is contributing to revenue growth.
• Auryxia sales remain strong, even with the introduction of a generic version.
• The company has sufficient cash to fund operations for the foreseeable future.
• Akebia is actively pursuing label expansion for Vafseo and advancing its pipeline.

Negatives

• Auryxia lost exclusivity in the U.S. in March 2025, which is expected to impact future revenue.
• The company is obligated to pay CSL Vifor decreasing quarterly tiered royalty payments ranging from a high single-digit percentage of the Company's net sales of Vafseo up to $450.0 million to mid-single digit percentage of the Company's net sales of Vafseo above $450.0 million, in each case, in the U.S. during a calendar year.
• The company identified a material weakness in its internal control over financial reporting related to inventory accounting.

Risks

• The impact of generic competition on Auryxia sales is uncertain.
• The company's ability to achieve and maintain profitability depends on the successful commercialization of Vafseo and Auryxia.
• The company is subject to complex regulatory schemes that require significant resources to ensure compliance.
• The company relies on third parties for manufacturing and distribution, which could lead to supply chain disruptions.
• The company has a material weakness in its internal control over financial reporting.

Future Outlook

Akebia expects to continue to generate revenue from its commercial products and collaborations and believes its existing cash resources and expected revenue will be sufficient to fund its operating plan for at least the next twelve months. The company is also exploring label expansion opportunities for Vafseo and advancing its pipeline of HIF-based molecules.

Management Comments

• The company believes its existing cash resources and the cash it expects to generate from product, royalty, supply and license revenues are sufficient to fund its current operating plan for the foreseeable future.

Industry Context

Akebia operates in the competitive biopharmaceutical industry, focusing on kidney disease. The company faces competition from established players and generic manufacturers. The approval of Vafseo provides Akebia with a unique oral treatment option for anemia in dialysis patients, but market acceptance and reimbursement remain key factors for its success.

Comparison to Industry Standards

• Akebia's performance can be compared to other biopharmaceutical companies focused on renal disease, such as Ardelyx, Inc., which markets IBSRELA and XPHOZAH.
• Comparable companies include those developing and commercializing treatments for anemia, such as Amgen (Epogen, Aranesp) and CSL Vifor (Mircera).
• The success of Vafseo can be benchmarked against other oral HIF-PH inhibitors like roxadustat (Evrenzo), marketed by Astellas and Bayer, in terms of market penetration and patient adoption.
• The company's ability to manage the loss of exclusivity for Auryxia can be compared to other pharmaceutical companies that have successfully navigated generic competition, such as Sanofi (Renagel, Renvela) and Shire Pharmaceuticals Group plc (Fosrenol).

Legal Proceedings

• Dr. Reddys Laboratories Limited filed an opposition to our issued Indian Patent No. 287720 covering the composition of matter of vadadustat in the Indian Patent Office.
• On November 6, 2024, Sandoz AG filed an opposition against our issued European Patent No. 3007695 covering vadadustat once daily dosing regimen in the European Patent Office.

Stakeholder Impact

• Shareholders: The company's profitability and revenue growth are positive for shareholders.
• Employees: The company's financial stability and growth prospects are positive for employees.
• Patients: The availability of Vafseo provides a new treatment option for anemia in dialysis patients.
• Customers: The company's ability to maintain supply and distribution of Auryxia and Vafseo is important for customers.
• Suppliers: The company's continued operations and growth are positive for suppliers.

Next Steps

• Continue commercialization efforts for Auryxia and Vafseo.
• Pursue label expansion opportunities for Vafseo.
• Advance the pipeline of HIF-based molecules.
• Manage the impact of generic competition on Auryxia sales.
• Maintain compliance with regulatory requirements.

Key Dates

Keywords

Akebia Therapeutics, Vafseo, Auryxia, Chronic Kidney Disease, Anemia, Financial Results, Q1 2025, Commercialization, Pharmaceuticals, HIF-PH Inhibitor